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Abstract In the pharmaceutical industry, improving
the early detection of drug-induced hepatotoxicity
is essential as it is one of the most important
reasons for attrition of candidate drugs during the
later stages of drug development. The first objec-
tive of this study was to better characterize differ-
ent cellular models (i.e., HepG2, HepaRG cells,
and fresh primary human hepatocytes) at the gene
expression level and analyze their metabolic cyto-
chrome P450 capabilities. The cellular models were
exposed to three different CYP450 inducers; beta-
naphthoflavone (BNF), phenobarbital (PB), and rifam-
picin (RIF). HepG2 cells responded very weakly to the
different inducers at the gene expression level, and this
translated generally into low CYP450 activities in the
induced cells compared with the control cells. On the
contrary, HepaRG cells and the three human donors
were inducible after exposure to BNF, PB, and RIF
according to gene expression responses and CYP450
activities. Consequently, HepaRG cells could be used in
screening as a substitute and/or in complement to pri-
mary hepatocytes for CYP induction studies. The sec-
ond objective was to investigate the predictivity of the
different cellular models to detect hepatotoxins (16 hep-
atotoxic and 5 nonhepatotoxic compounds). Specificity
was 100% with the different cellular models tested.
Cryopreserved human hepatocytes gave the highest sen-
sitivity, ranging from 31% to 44% (depending on the
donor), followed by lower sensitivity (13%)for HepaRG
and HepG2 cells (6.3%). Overall, none of the models
under study gave desirable sensitivities (80–100%).
Consequently, a high metabolic capacity and CYP in-
ducibility in cell lines does not necessarily correlate with
a high sensitivity for the detection of hepatotoxic drugs.
Further investigationsare necessaryto compare different
cellular models and determine those that are best suited
for the detection of hepatotoxic compounds.
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Introduction
Drug-induced liver injury is one of the most common
reasons that accounts for the attrition of candidate
drugs during the later stages of drug development.
Consequently, early detection of drug-induced hepa-
totoxicity is essential before compounds are tested in
animals and enter clinical trials to save time and
resources (O’Brien et al. 2006). McDonald and
Robertson (2009) calculated that out of 51 drugs
taken off the market, 29 and 33% were withdrawn
due to hepatotoxicity and cardiotoxicity, respectively.
Primary human hepatocytes (HH) are considered as
the gold standard model for xenobiotic metabolism
and cytotoxicity studies (Guillouzo et al. 2007). How-
ever, the scarce availability of fresh human liver sam-
ples,complicated isolation procedures,limited lifespan,
inter-individual variability, and cost constitute serious
limitations for the use ofsuchinvitro systems inscreen-
ing (Madan et al. 2003). To overcome these limitations,
immortalized liver-derived cell lines were proposed as
anideal alternative tostudy drug metabolismbecause of
their unlimited availability and phenotypic stability. A
first alternative is the widely used human hepatocellular
carcinoma cell line HepG2. These cells are highly
differentiated and display many of the genotypic
features of normal liver cells (Sassa et al. 1987).
Consequently, HepG2 cells can be used to screen
the cytotoxicity potential of new chemical entities
at the lead generation phase (Gerets et al. 2009).
Nevertheless, their main limitation is linked to their low
metabolic capacities compared with primary hepatocytes
(Xu et al. 2004) whichmake themappropriate for testing
the toxicity of the parent molecule but less suited for
metabolite toxicity testing. Westerink and Schoonen
(2007) showed that HepG2 cells have low levels of
cytochromes (CYPs) but normal levels of phase II
enzymes with the exception of UDP-glucuronosyl
transferases.
Promising new cellular models such as HepaRG
cells have also been developed to tackle the problem
of low metabolic profiles observed in HepG2 cells.
Indeed, HepaRG cells, a human hepatocellular carci-
noma cell line (Gripon et al. 2002) composed of a
mixture of both hepatocytes-like and biliary-like cells,
retain a drug metabolism capacity comparable to that
of primary HH without inter-donor variability and
functional instability with time in culture that has been
observed in primary cells (Lambert et al. 2009).
HepaRG cells were shown to maintain hepatic func-
tions and expression of liver-specific genes at levels
comparable to HH (Anthérieu et al. 2010).
The aim of our investigations was to better charac-
terize three cellular models, namely HepG2, HepaRG
cells and primary HH with a focus on gene expression,
CYP activity and cytotoxicity evaluation. To the best
of our knowledge, this combined approach has been
very rarely attempted in the same study. In a first
instance, the different cellular models were exposed
to beta-naphthoflavone (BNF), phenobarbital (PB),
and rifampicin (RIF) to study their gene expression
modulation using an absorption–distribution–metabo-
lism–excretion (ADME) array and their cytochrome
P450 enzyme activities (CYP1A2, 2B6, and 3A4).
Subsequently, they were exposed to 21 reference com-
pounds with known hepatotoxic potentials in humans.
The objectives of the present study were to (1) compare
mRNA levels of genes involved in metabolism of con-
trol cells and of cells exposed to inducers, (2) determine
CYP450 activities after exposure to the three inducers,
and (3) evaluate the potential of the different cellular
models to detect hepatotoxic compounds.
Materials and methods
Materials
All compounds and reagents (i.e., BNF, RIF, aflatox-
ine B1, amiodarone, astemizole, cerivastatin, danazol,
flutamide, ketoconazole, labetalol, aspirin, chlorprom-
azine, clofibrate, cyclosporine A, furazolidone, imip-
ramine, tacrine, tamoxifen, betaine HCl, flufenamic
acid, isoproterenol, praziquantel, and primidone) were
of analytical grade and were purchased from Sigma-
Aldrich (Saint Louis, USA) except PB which was
obtained from Certa (Braine-L’Alleud, Belgium).
RNeasy Mini kits were purchased from Qiagen (Valencia,
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obtained from Codelink (now Applied Microarrays,
Tempe, USA).
Cellular models
The human hepatocellular carcinoma (HepG2) cell
line, purchased from the European Collection of Cell
Cultures(ECCAC,Salisbury,UK)wasmaintainedasan
adherent cell line in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum,
50 U/ml penicillin, 50 μg/ml streptomycin, 2 mmol/l L-
glutamine, and 1× nonessential amino acids at 37°C in a
5% CO2:95% air-humidified atmosphere. Cells were
passaged as needed using 0.5% trypsin-EDTA. All the
cell culture solutions were purchased from BioWhittaker
Inc (Walkersville, MD, USA).
The HepaRG cell line is derived from a liver tumor
of a female patient suffering from hepatocarcinoma
(Gripon et al. 2002). HepaRG cells were purchased
from Biopredic International (Rennes, France) as con-
fluent monolayer (ca. 1×10
6 cells per well) in 6-well
plates with the associated medium. Six-well plates
were used for gene expression and CYP450 evalu-
ation. HepaRG cells platedi n9 6 - w e l lp l a t e sw e r e
used for the cytotoxicity experiments. For both formats,
the medium used was composed of Williams E
with Glutamax-I added with 100 IU/ml of penicillin,
100 μg/ml of streptomycin, 4 μg/ml of bovine insulin
and 5×10
−5 M of hydrocortisone hemisuccinate. Before
shipment, thecellswereallowed to proliferateand when
confluence was reached, the cells were cultured for
2 weeks in the same medium supplemented with 2%
dimethylsulfoxide(DMSO)inordertoobtainmaximum
differentiation. After shipment, the medium was
changed to high DMSO containing medium. Media
wererenewedevery 2–3da ys .T hela stme di umre ne wa l
before starting the induction period was done with
“Enriched”medium.Onthedayofcompoundexposure,
“induction”mediumwasused.Detailsofbothmediaare
proprietary (Biopredic).
Primary cultures of HH, freshly isolated from three
different donors (for characteristics, see Table 1), were
purchased from Biopredic International (Rennes,
France) as confluent monolayers (ca. 1.5×10
6 cells per
well) in 6-well plates pre-coated with a single film of
collagen. This format was used to generate mRNA and
CYP activity data. Fresh HH were seeded in Williams E
medium supplemented with 10% fetal calf serum,
100 U/μl penicillin, 100 μg/ml streptomycin, 1 μg/ml
insulin, 2 mM L-glutamine, and 1 μg/ml bovine serum
albumin. Upon arrival, the Biopredic proprietary ship-
ping medium was replaced with Williams E medium
containing Glutamax-I, penicillin (100 IU/mL), strepto-
mycin (100 μg/mL), bovine insulin (4 μg/mL),
and hydrocortisone hemissuccinate (50 μM). The
hepatocytes were incubated in a 5% CO2:95% air
humidified atmosphere at 37°C for ca. 2 h before
starting the treatment period in the presence of the
reference inducers.
Cryopreserved primary HH from three different
donors were purchased from CellzDirect/Invitrogen
(Cheshire, UK; for characteristics, see Table 1). This
format was used to perform the cytotoxicity experi-
ments. Cryopreserved HH were thawed based upon
CellzDirect’s standard method. In brief, hepatocytes
were thawed at 37°C, poured into pre-warmed (37°C)
CHRM™ thawing medium at a ratio of one vial/50 ml.
The cells were centrifuged at 100 g for 10 min, resus-
pended in 2–3m lc o l d( 4 ° C )C H P M ™ plating medium
and cell viability determined. The cells were seeded in a
collagen-coated E-plate at a density of 20,000 cells/well
and allowed to attach in a 5% CO2:95% air-humidified
atmosphereat37°Cforca.4–6hafter whichthemedium
was changed to Williams E medium containing
Glutamax-I, penicillin (100 IU/mL), streptomycin
(100 μg/mL), bovine insulin (4 μg/mL), and hydrocor-
tisone hemissuccinate (50 μM). Subsequently, 10 μlo f
compound was added to the wells to start the incubation.
Toxicogenomics and CYP activities determined
after exposure of the different cellular models
to inducers (6-well format)
Treatment with inducers
The cells of the 3 cellular models were exposed to
BNF (25 μM), PB (500 μM), and RIF (25 μM) for
24 h for gene expression evaluation and for 72 h for
CYP activity measurements, with medium renewal
every 24 h. BNF was used as reference inducer for
CYP1A2, PB for CYP2B6, and RIF for CYP3A4.
Stock solutions were prepared in DMSO and further
100× diluted in the adequate culture medium (0.1%
(v/v) final DMSO concentration). Control cells were
exposed to 0.1% (v/v) DMSO. The cells were then
incubated in a 5% CO2:95% air humidified atmosphere
at 37°C.
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TotalRNAwas isolated fromthe cells using the RNeasy
Mini kit according to the manufacturer instructions
(Qiagen Benelux, Venlo, The Netherlands). RNA quan-
tity was assessed with the nanodrop spectrophotometer
(Isogen, IJsselstein, The Netherlands) and RNA quality
was checked with the Agilent™ bioanalyzer 2,100
(Agilent Technologies, Massy, France). The human
ADME microarrays were purchased from Applied
Microarrays. Each array was composed of 1,250 differ-
ent probes. The genes present on the microarray are all
part of the human whole genome microarray which has
been extensively used in the literature (Guo et al. 2006;
Hiyama et al. 2009; Kamei et al. 2009). To perform
cDNA amplification and hybridization the Codelink™
iExpress iAmplify cRNA Prep & Hyb Kit of Applied
Microarrays (Tempe, AZ, USA) was used according to
the manufacturer’s instructions. The arrays were
scanned using the GenePix Array Scanner from Axon
(Axon Instruments, Foster City, CA, USA) using laser
excitation of the fluor at 635-nm wavelengths for the
Cy5 labels. The gene expression data were analyzed
using a two-sample t test with unequal variances. Sig-
nificant differentially expressed probes have been
defined as having an adjusted p value of <0.05
(Benjamini and Hochberg 1995) and a fold change
of >2 for upregulated genes or <−2 for downregulated
genes. Principal component analysis (PCA) was used to
compare the different cellular models. Principal compo-
nent analysis provides a means to reduce high-
dimensional geneexpressiondata intofew principalcom-
ponents. Gene expression profiles were considered to be
similar when data were close in PCA space.
CYP450 enzymatic activities determination
after induction
The cells were exposed to the different inducers for
3 days, with every day medium renewal. At the end of
the treatment, the cells were washed, harvested in
50 mM Tris-HCl buffer and the microsomal fractions
Table 1 Human hepatocytes donor demographics and characterization
Cell
preparation
Sex Age
(years)
Ethnicity Liver pathology Functional control provided by the supplier
Activity in nmol h
−1 mg
−1 protein Activity in pmol min
−110
−6
cells
CYP1A2 CYP3A4/5 Paracetamol CYP1A2 CYP2B6 CYP3A
Glucuronidation Sulfation
Donors of freshly isolated human hepatocytes
a
HH1 ♂ 71 Caucasian Colorectal
metastasis
4.1 12.7 11.2 4.2
HH2 ♀ 82 Caucasian Hepatic
metastasis
b
5.4 17.1 20.3 8.0
HH3 ♂ 47 Caucasian Liver metastasis
c 0.8 17 11 2.2
Donors of cryopreserved human hepatocytes
d
Hu4198 ♀ 9 Caucasian Anoxia/head
trauma
13.4 5.29 22.7
Hu4199 ♀ 63 Caucasian CVA 12.1 2.29 134
Hu4205 ♂ 43 Caucasian Anoxia 11.0 7.94 105
CVA cerebrovascular accident
aThe table gives information about three donors of freshly isolated human hepatocytes for microarray experiments. For each of the
donors, details are described regarding their sex, age, ethnicity, and liver pathology. Control CYP1A2, CYP3A4/5 (phase I enzymes),
and paracetamol glucuronidation and sulfation (phase II enzymes) activity are mentioned for each of the donors
bFrom colon adenocarcinoma
cFrom colon cancer
dThe table gives information about three donors of cryopreserved human hepatocytes for cytotoxicity experiments. For each of the
donors, details are described regarding their sex, age, ethnicity, and cause of death. Control CYP1A2, CYP3A4/5 (phase I enzymes),
and CYP2B6 activity are mentioned for each of the donors
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1996). CYP marker activities were measured accord-
ing to methods adapted from the literature (Faucette
et al. 2000; Kanazawa et al. 2004). Briefly, micro-
somes prepared from monolayers of the different cell
types were used for the analysis of 7-ethoxyresorufin
O-dealkylation, bupropion hydroxylation, and mida-
zolam 1′-hydroxylation as marker activities of human
CYP1A2, CYP2B6, and CYP3A4, respectively. Incu-
bations were performed in 50 mM phosphate buffer at
37°C using a NADPH regenerating system (BD Bio-
Sciences, San Jose, CA, USA) and CYP450 substrate
7-ethoxyresorufin (10 μM), bupropion (200 μM), or
midazolam (3 μM) using the following conditions:
100, 500, and 50 μg/ml microsomal protein and incu-
bation time of 60, 20 and 5 min for CYP1A2,
CYP2B6, and CYP3A4, respectively. Reactions were
stopped by the addition of ice-cold acetone and clear
supernatants analyzed for the presence of metabolites.
The amount of resorufin formed was measured by
fluorimetry (1ex/em, 530/590 nm). The amounts of
hydroxybupropion and 1′-hydroxymidazolam were
determined by LC-MS/MS assays (Shah et al. 2000).
Supernatants were mixed to propranolol hydrochloride
as internal standard and injected into a HPLC system
(Agilent technologies, Palo Alto, USA) equipped with
a XDB-C18 column (50×2.1 mm, 5 μm). Quantifica-
tion of hydroxybupropion and 1′-hydroxymidazolam
were performed with a Quattro Micro mass spectro-
photometer (Waters-Micromass, Manchester, UK).
Elution was performed using a mixture of solvent A
consisting of 0.1% TFA in water adjusted to pH 2.4
with NH4OH and solvent B consisting of ACN. For
the hydroxybupropion determination, the proportion
of solvent B in the mobile phase was increased from
20% to 90% in 7.5 min, remained at 90% for 2 min
and decreased from 90% to 20% thereafter (total run
of 16 min). For the determination of 1′-hydroxymida-
zolam, the proportion of solvent B in the mobile phase
was increased from 25% to 90% in 7 min, remained at
90% for 3 min and decreased from 90% to 25%
thereafter (total run of 15 min). The peak areas of the
m/z 256→139 (hydroxybupropion) and m/z 342→324
(1′-hydroxymidazolam) product ion were measured
against the peak areas of the m/z 260→116 of
the internal standard. Microsomal proteins were
determined using the BCA Protein Assay adapted to
microtiter plate (Smith et al. 1985). Activities were
compared with those in corresponding vehicle-treated
cells with data expressed as fold induction over
controls.
Effects of human hepatotoxicants and
nonhepatotoxicants on the different cellular models
(96-well plate format)
Treatment with hepatotoxic and nonhepatotoxic
compounds
The three cellular models were treated with 21 refer-
ence compounds known to cause hepatotoxicity or not
(eight severely hepatotoxic compounds, i.e., aflatoxine
B1, amiodarone, astemizole, cerivastatin, danazol,
flutamide,ketoconazole, and labetalol;eight moderately
hepatotoxic compounds, i.e., aspirin, chlorpromazine,
clofibrate, cyclosporine A, furazolidone, imipramine,
tacrine, and tamoxifen; and five nonhepatotoxic com-
pounds, i.e., betaine HCl, flufenamic acid, isoprotere-
nol, praziquantel,and primidone). The compounds were
classified according to O’Brien et al. (2006)a n dW e n
and Zhou (2009).
Time-dependent cell response profiling using real-time
cell analyzer
The xCELLigence System from Roche Diagnostics
(Vilvoorde, Belgium) measures electrical impedance
across microelectrodes integrated into the bottom of
tissue culture E-Plates. The impedance measurement
provides quantitative information on the biological
status of the cells, including cell number, viability, and
morphology. The 96-well E-plates were coated with
collagen (Collagen RSolution0.2%(Serva,Heidelberg,
Germany) for HepG2 and HepaRG cells and Rat Tail
Collagen, type 1 (BD Biosciences, Erembodegem,
Belgium) for cryopreserved HH) according to the
manufacturer’s recommendations. Preliminary experi-
ments determining the best coating and the cell density
were performed as previously described in Atienzar et
al. (2011). After background reading the appropriate
number of cells was added to the plate (10,000 cells/
wellfor HepG2cells,20,000cells/wellforcryopreserved
primary hepatocytes, and HepaRG plates were seeded at
Biopredic until confluence). The cells were allowed to
attach at room temperature for 30 min, after which they
were placed on the reader in the incubator for continuous
recording of impedance overnight for HepG2 and
HepaRG cells and for 4–6 h for primary hepatocytes.
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Stock solutions of 100 mM were used to prepare three
other stock solutions at 0.1, 1, and 10 mM in 100%
DMSO. These solutions were further diluted in water
and added to the wells. Final concentrations in the plates
were 0.1, 1, 10, and 100 μM, and the final DMSO
percent was 0.1%. Each treatment condition was
measured intriplicate except for the control cells exposed
to0.1% DMSO (n06) and for the positive controls (n02,
0.00125, 0.0025, and 0.005% Triton X-100). For three
compounds (amiodarone, ketoconazole, and furazoli-
done) solubility problems occurred at 100 mM and a
stock solution of 50 mM was prepared, so that the final
concentrations in the plate were 0.05, 0.5, 5, and 50 μM.
The cells were monitored in real time, at 37°C in a
humidified 5% CO2:95% air atmosphere, using the mul-
tiplate xCELLigence platform. Intervals for data collec-
tion were every 10 min after compound addition for 2 h
followed by every 30 min for 72 h. To quantify the cell
status based on the measured cell-electrode impedance, a
parameter termed cell index (CI) is derived, according to
the following equation (Abassi et al. 2009):
Cl ¼ max
i¼1;:::;N
Rcell fi ðÞ
Rb fi ðÞ
  1

where Rb(f)a n dRcell(f) are the frequency-dependent elec-
trode resistances (a component of impedance) without
cell or with cells present, respectively. N is the number of
thefrequencypointsatwhichtheimpedanceismeasured.
Thus, CI is a quantitative measure of the status of the
cells in an electrode-containing well. Under the same
physiological conditions, more cells attaching onto the
electrodes leads to larger Rcell(f) value, leading to a larger
value for CI. Decrease in CI correlates generally well to
cell death despite potential confounding factors. Further-
more, for the same number of cells present in the well, a
change in the cell status such as morphology will lead to
a change in the CI. A “normalized CI” at a given time
point is calculated by dividing the CI at the time point by
the CI at a reference time point. Thus, the normalized CI
is 1 at the reference time point. The normalization was
done by using the last time point before compound
addition.Thisallowscomparingmorepreciselytheeffect
of the different concentrations tested versus the control.
The CI values presented here were calculated from trip-
licate values (technical replicates) and presented as aver-
age±standard deviation. Each cellular model has been
repeated three times (biological replicates). LC50 values
were determined after 48 and 72 h using an internally
developed excel macro. In order to evaluate the perfor-
mance of the different cellular models to detect hepato-
toxic and nonhepatotoxic compounds, the sensitivity and
specificity percentages were calculated. The sensitivity is
defined as the ability of a test system to predict the
positive outcome under evaluation (i.e., hepatotoxicity).
The specificity represents the ability of a test system to
predict the negative outcome under evaluation (i.e.,
nonhepatotoxicity).
Results
Toxicogenomics and CYP450 activities after exposure
of the different cellular models to CYP450 inducers
Gene expression analysis
The PCA representing the gene expression intensities
observed in the three cellular models exposed to 0.1%
DMSO and to the three inducers (BNF, PB, and RIF)
is shown in Fig. 1a, b, respectively. The PCAs have
been performed on the normalized intensities of the
samples to see how the samples group together. The
data were normalized against all housekeeping genes
present on the microarray. Each model has been done
in triplicate and each point in the PCA plot represents
the gene expression results of an individual array. One
of the replicates of donor 2 (HH2) was a clear outlier
(data not shown) due to a technical issue (low hybrid-
ization to the array) and therefore omitted from further
analysis. The PCAs show that the technical replicates
per cellular model are relatively well clustered (Fig. 1a).
HepG2 and HepaRG cells were equally separated from
the HH donors HH2 and HH3 in the control condition
(Fig. 1a). HepaRG cells are closer to HH1 compared
with HepG2 cells. After induction, HepaRG cells are
more closely related in space to the human donors than
HepG2 cells (Fig. 1b). Only limited changes in gene
expression pattern, after exposure to any of the three
inducers, could be observed for HepG2 cells in compar-
ison to the HepaRG and three human donor cells
(Fig. 1b).
Gene expression analysis within the control condi-
tion is shown in Table 2 (upper part). Herein, each
cellular model within the control condition will be com-
pared with each other and the number of differentially
expressed probes calculated. Differentially expressed
probes have been arbitrary defined as having a fold
74 Cell Biol Toxicol (2012) 28:69–87change of >2 for upregulated genes or <−2 for down-
regulatedgenes.Inaddition,significantresults(p<0.05)
aremarkedwithanasterisk.Thelargestdifferenceinthe
number of differentially expressed probes within the
control condition was observed between HH and
HepG2 cells, with an average of 599 differentially
expressed probes (out of 1,250 probes). Between
HepG2 and HepaRG cells an average of 490 probes
Fig. 1 Principal component
analysis of gene expression
data from HepG2, HepaRG,
and human hepatocytes
exposed to solvent and
three inducers. PCAwas
performed on the normalized
intensities of the control
samples (cells exposed
to 0.1% DMSO) (a)a n d
of cells exposed to BNF,
PB, and RIF (b). Each model
has been done in triplicate
and each point in the
PCA plot represents the
gene expression result of
a separate array. One of
the triplicates of donor
2( HH2) was an outlier due
to technical issue and for
that reason not taken into
account to make any
further calculations
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HH and HepaRG cells and among the different donors
of the HH was comparable, with an average of 315 and
326 differentially expressed probes, respectively. After
induction, for each cellular model the number of differ-
entially expressed probes was calculated in the control
versus the induced condition (Table 2, lower part). An
average of 73 probes were differentially expressed (cut-
off set at 2) in HepG2 cells compared with an average of
107probesinHHdonors(100,131,and91differentially
expressed probes in donors 1, 2, and 3, respectively).
Table 3 presentsa comparison ofthe geneexpression
fold changes within the control condition for a total of
39 metabolizing genes (25 phase I and 14 phase II
metabolizing genes) and six phase III transporter genes
(three efflux and three uptake drug transporters),
that were present on the human ADME array. The
values in the table represent the fold changes between
two cellular models that were compared within the
vehicle-control condition. All possible combinations
are represented.
HepaRG vs. HepG2 Twenty-one of 45 genes were
significantly higher expressed (cut-off02, p<0.05) in
HepaRG cells compared with HepG2 cells. Only glu-
tathione transferase M3 gene was significantly less
expressed (2.95-fold) in HepaRG compared with
HepG2 control cells. For the remaining 23 genes,
similar expression levels were obtained between the
two models. The CYP3A4 gene, one of the most
Table 2 Comparison of gene
expression changes in control
and treated cells from different
cellular models
The table represents the number
of differentially expressed
probes among the different
cellular models in the control
condition (upper part) and after
exposure to the
different inducers (lower part).
The differentially expressed
probes have been defined as
having a fold change of >2 for
upregulated genes or <−2 for
downregulated genes. Note that
for any comparison noted AA.
BB, the fold change is computed
as the mean of the first group
divided by the mean of the
second group: mean (AA)/mean
(BB)
SD standard deviation
Up Down Either Mean±SD
Control condition
HH1.HH2 216 50 267 326±72
HH1.HH3 343 63 406
HH2.HH3 154 150 304
HH1.HepG2 611 113 724 599±132
HH2.HepG2 434 178 612
HH3.HepG2 326 135 461
HH1.HepaRG 144 96 240 315±66
HH2.HepaRG 133 230 363
HH3.HepaRG 99 243 342
HepG2.HepaRG 93 397 490 490
Control vs. induced condition
HepG2
DMSO.BNF 31 61 92 73±22
DMSO.PB 17 60 77
DMSO.RIF 27 22 49
HepaRG
DMSO.BNF 106 25 131 85±40
DMSO.PB 35 25 60
DMSO.RIF 41 22 63
HH1
DMSO.BNF 74 50 124 100±21
DMSO.PB 46 44 90
DMSO.RIF 26 61 87
HH2
DMSO.BNF 64 81 145 131±38
DMSO.PB 39 121 160
DMSO.RIF 39 49 88
HH3
DMSO.BNF 51 35 86 91±13
DMSO.PB 76 29 105
DMSO.RIF 59 22 81
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higher expressed in HepaRG cells (19.1 times, p<0.05)
compared with HepG2. Other genes such as CYP2C18
and the uptake transporter, solute carrier family 22 drug
transporter, were also significantly higher expressed in
HepaRG cells compared with HepG2 cells (56 and 100
times, respectively).
Primary HH vs. HepG2 Thirty-three of 45 genes were
higher expressed (cut-off02) in the HH compared
Table 3 Summary of the gene expression fold changes among the different cellular models
HH1 vs 
HepG2
HH2 vs 
HepG2
HH3 vs 
HepG2
HH1 vs 
HepaRG
HH2 vs 
HepaRG
HH3 vs 
HepaRG
HH1 vs 
HH3
HH2 vs 
HH3
HH1 vs 
HH2
CYP1A1 1.73 2.35* 1.21 1.04 1.36 -1.43 -1.66 2.26 1.16 1.94
CYP1A2 2.04 2.76* 1.84 1.44 1.36 -1.11 -1.42 1.92 1.28 1.50
CYP11A1 -1.74 1.36 -1.17 1.55 2.36* 1.49 2.70* -1.14 -1.81 1.59
CYP17A1 1.40 1.92 1.10 -1.24 1.37 -1.27 -1.75 2.39 1.37 1.74
CYP2A13 2.11 4.14* 4.37 3.31 1.96 2.07 1.57 1.25 1.32 -1.06
CYP2C18 55.9* 579* 388* 531* 10.4* 6.94* 9.51* 1.09 -1.37 1.49
CYP2D6 1.82 67.8* 94.4* 63.3* 37.2* 51.8* 34.7* 1.07 1.49 -1.39
CYP2E1 5.53* 51.6* 55.11 49.4* 9.33* 9.96 8.92* 1.05 1.12 -1.07
CYP2F1 2.05 -1.30 -1.05 1.17 -1.21 -1.53 -1.54 -1.53 1.00 1.26
CYP26A1 1.15 58.4* 2.19 1.09 24.6* 1.90 -1.06 26.1* 2.01 13.0
CYP26B1 2.01* 1.54 -1.51 -1.59 -1.30 -3.11 -3.19 2.45 1.02 2.39
CYP3A4 19.1* 232* 327* 104* 12.1* 17.1* 5.45* 2.23 3.14 -1.41
CYP3A7 2.96* 8.32* 5.65 6.18* 2.81 -1.29 2.08* 1.35 -1.09 1.47
CYP4B1 18.5* 1.93 1.20 -1.54 -9.59* -15.4* -28.5* 2.97* 1.85 1.60
CYP51A1 1.23 1.69 1.34 1.33 -1.60 -1.29 -1.04 1.35 -1.23 -1.24
CYP7A1 36.1 31.0 41.0 30.0 -1.17 1.14 -1.20 1.03 1.37 -1.32
CYP7B1 21.5* 42.1* 26.2* 10.2* 1.96 1.22 -2.10 4.11 2.56 1.61
CYP8B1 1.83 3.04* 1.79 4.02* 1.66 -1.02 2.20 -1.32 -2.24 1.69
Epoxide hydrolase 1 (s1) 13.2* 4.49* 3.38* 8.90* -2.93* -3.89 -1.48 -1.98 -1.00 1.33
Epoxide hydrolase 1 (s2) 7.72* 3.97* 4.52* 4.53* -1.94 -1.71 -1.70 -1.14 -1.00 -1.14
Epoxide hydrolase 2 3.32* 2.65* 2.04* 2.54* -1.25 -1.63 -1.31 1.04 -1.24 1.30
Flavin containing monooxygenase 1 5.62* 2.82 7.13* 32.4* -1.99 1.27 5.75* -11.5 -4.54 -2.53
Flavin containing monooxygenase 2 3.79 3.39 1.47 1.22 -1.12 -2.58 -3.10* 2.77 1.20 2.30
Flavin containing monooxygenase 4 4.22* 4.43* 3.46* 3.28* 1.05 -1.22 -1.29 1.35 1.05 1.28
Flavin containing monooxygenase 5 4.41* 4.26* 5.36* 1.44 -1.03 1.22 -3.05* 2.95* 3.71 -1.26
Glutathione S-transferase A1 6.97* 2.85* 2.11* 4.15* -2.44 -3.29* -1.68 -1.46 -1.96 1.35
Glutathione S-transferase theta 1-s1 2.56* 2.09* 2.43* 1.85 -1.22 -1.05 -1.38 1.13 1.31 -1.16
Glutathione S-transferase theta 1-s2 2.49* 2.05* 2.11* 1.62 -1.22 -1.18 -1.54 1.26 1.30 -1.03
Glutathione S-transferase theta 2 1.40 1.58 1.24 1.17 1.13 -1.13 -1.20 1.35 1.06 1.27
Glutathione transferase M3 -2.95* -1.89 -2.04 -1.77 1.56 1.45 1.67 -1.07 -1.15 1.08
Heme oxygenase (decycling) 1 -1.01 -1.09 -1.06 -1.85 -1.08 -1.05 -1.83 1.70 1.75 -1.03
Heme oxygenase (decycling) 2 1.33 1.61 1.23 1.31 1.21 -1.08 -1.01 1.23 -1.07 1.31
Sulfotransferase family 1E1 3.25 3.75* 2.28 1.77 1.15 -1.43 -1.84 2.12* 1.29 1.65
Sulfotransferase family 1B1 11.6 15.7 18.2 8.63 1.35 1.57 -1.34 1.82 2.11 -1.16
Sulfotransferase family 2B1 2.26* 2.50 2.14 -1.03 1.11 -1.05 -2.32 2.57 2.20 1.17
UDP glucuronosyltransferase 2B15 5.56* 3.75* 2.14 5.97* -1.48 -2.60 1.07 -1.59 -2.79 1.75
UDP glycosyltransferase 8 1.43 1.75 1.35 1.24 1.22 -1.06 -1.16 1.42 1.10 1.29
UDP-glucose ceramide 
glucosyltransferase
2.82* 2.06 2.31 2.22 -1.37 -1.22 -1.27 -1.08 1.04 -1.12
UDP-glucose ceramide 
Glucosyltransferase-like 1
-1.62 -1.69 -2.63* -1.64 -1.04 -1.01 -1.01 -1.03 -1.60 1.55
ATP-binding cassette (ABCG2) 1.05 2.67* 1.51* 1.47* 2.55* 1.44 1.41 1.81 1.02 1.77
Solute carrier family 10 (SLC10A1) 12.2* 56.8* 29.3* 38.6* 4.65* 2.40* 3.16* 1.93* -1.32 1.94
ATP-binding cassette (ABCB1) 1.84* 2.48* 1.47* 3.00* 1.35 -1.25 1.63* -1.21 -2.04 1.70
Solute carrier family 22 (SLC22A1) 99.9* 220* 190* 114* 2.21 1.90* 1.14 1.93 1.66 1.16
Solute carrier family 22 (SLC22A7) 1.89* 2.21* 1.42 11.3* 1.17 -1.33 -1.41 1.65 1.06 1.56
ATP-binding cassette (ABCC2) 1.70* 4.80* 5.88* 4.43* 2.82* 3.46* 2.60* 1.08 1.33 -1.23
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Gene list
Human Primary Hepatocytes 
vs. HepG2 
Human Primary Hepatocytes 
vs. HepaRG 
Human Primary Hepatocytes vs. 
Human Primary Hepatocytes
HepaRG 
vs 
HepG2
The numerical value indicates the fold change among the cellular models that are compared (e.g., CYP1A1 01.73 means that the
CYP1A1 gene is 1.73 times higher expressed in HepaRG cells than in HepG2 cells); differentially expressed genes that are upregulated
by at least a factor of 2 are colored in red, and those which are downregulated by at least a factor of −2 are colored in green
*p<0.05, significant difference between the cellular models
Cell Biol Toxicol (2012) 28:69–87 77with HepG2 at least in one of the three donors. How-
ever, out of these 33 genes, 20 genes were systemat-
ically higher expressed in all three donors. For
instance, CYP2C18 and CYP3A4 were on average
499 and 221 times higher expressed in primary cul-
tures of hepatocytes compared with HepG2 cells, re-
spectively. Only two genes (glutathione transferase M3
and UDP-glucose ceramide glucosyltransferase-like one
gene) were higher expressed in HepG2 cells compared
with HH2.
Primary HH vs. HepaRG Six genes, including the
CYP3A4 gene, were systematically higher expressed
(cut-off of 2) in all three preparations of HH compared
with HepaRG cells. For instance, CYP2D6 was 35–50
times higher expressed at the mRNA level in fresh HH
as compared with HepaRG cells. This result was
expected as the HepaRG cells were derived from
an individual that is a poor CYP2D6 metabolizer
(Guillouzo et al. 2007). Only CYP4B1 gene was
clearly higher expressed in HepaRG cells compared
with the three donors (with a factor of minimum ca.
10). For all the other genes, similar expression values
were obtained in both models.
Among the HH donors Small differences in gene ex-
pression among the hepatocytes from the three donors
were observed. The highest difference among the three
donors was observed for genes CYP26A1 and flavin
containing monooxygenase 1. The largest difference
between the donors was observed between donor one
and three, with 12 differentially expressed genes.
Gene expression changes after exposure to BNF,
PB, and RIF are presented in Table 4. To improve data
visualization, a rectangle is drawn when the gene is
regulated in the same direction in all different cellular
models (five of five) and a dashed rectangle is drawn
when four out of five cellular models are regulated in
the same direction irrespective of the values of the
factors.
BNF Five genes (CYP2D6, flavin containing mono-
oxygenase 5, sulfotransferase family 1E1, UDP-glucose
ceramide glucosyltransferase-like 1, and solute carrier
family 10) were down-regulated and 2 genes (CYP1A1
and heme oxygenase 1) were up-regulated in all models
following BNF treatment. Six genes (CYP1A2 (up),
CYP2E1 (down), CYP3A7 (down), CYP4B1 (down),
epoxide hydrolase 1 (s1) (up), and ATP-binding cassette2
(ABCC2) (up)) were regulated in the same direction in all
models except for one human hepatocyte donor.
CYP7A1, flavin containing monooxygenase 1 and
solute carrier family 22 (SLC22A1) were up-
regulated in HepG2 cells and downregulated in
the other models. When comparing the three HH
donors, a similar trend in gene expression was
found between donors 1 and 2. Donor 3 showed a
slightly different expression pattern.
PB Four genes (CYP3A7, epoxide hydrolase 1 (s1),
hemeoxygenase1,andATPbindingcassette(ABCB1))
were upregulated by PB in all cellular models and two
genes (sulfotransferase family 1E1 and 1B1) were
downregulated. The genes CYP2A13 and CYP3A4
were downregulated in HepG2 cells and upregulated
in the other cellular models and vice versa for CYP7A1.
All three donors responded in a similar way for most
genes.
RIF Five genes (CYP3A7, epoxide hydrolase 1 (s1
and s2), heme oxygenase 1, and ATP-binding cassette
(ABCB1)wereupregulatedbyRIFinall cellular models.
CYP3A4 was upregulated in all models, except for
HepG2 cells. All three HH donors responded in a similar
way for most genes.
CYP activities measurement
Table 5b represents the fold induction of CYP1A2,
2B6 and 3A4 activities in the three cellular models
exposed to the different inducers. Experiments were
performed in triplicate and the average fold induction
is presented. The individual basal and induced activi-
ties are presented in Table 5a.
HepG2 Treatment with BNF caused a 9.1-fold in-
crease in CYP1A2 activity, whereas PB and RIF did
not have any effect on the CYP2B6 and 3A4 activity,
respectively.
HepaRG BNF treatment increased the CYP1A2 ac-
tivity 35.7-fold compared with the vehicle-treated
HepaRG cells. PB treatment also increased CYP2B6
activity 8.7-fold. CYP3A4 activity was increased
42.4 and 36.6 times after RIF and PB treatment,
respectively.
78 Cell Biol Toxicol (2012) 28:69–87HH Treatment with BNF caused on average a 10-fold
increase in CYP1A2 activity. No data for CYP2B6
activity was reported for donor three due to a technical
problem.TreatmentwithPBcauseda 12.8- and 8.3-fold
increase in CYP2B6 activity for donor 1 and 2, respec-
tively. Donor 3 showed a 10.6-fold increase in CYP3A4
activityaftertreatmentwithRIF,whereasdonors1and2
showed only a 3.7- and 2.1-fold increase, respectively.
PB also induced CYP3A4 activity in all three donors in
the range two to six times.
Comparing all models HepaRG cells were the most
inducible model, for instance, CYP1A2 was induced
35.7× (BNF), CYP2B6 8.7× (PB), and CYP3A4 42.4×
(RIF). The HH donors responded moderately to the differ-
ent inducers. CYP1A2 induction showed little variability
Table 4 Summary of the gene expression fold changes in the different cellular models after exposure
Gene list HepG2 HepaRG HH1 HH2 HH3 HepG2 HepaRG HH1 HH2 HH3 HepG2 HepaRG HH1 HH2 HH3
CYP1A1 4.21* 3.1* 3.85 4.14 1.02 1.16 -1.05 -1.08 1.44 5.80 / / / / /
CYP1A2 1.23 1.61 6.83 3.69 -1.31 1.11 -1.01 -1.03 1.27 5.91 / / / / /
CYP11A1 // / / / // / / / // / / /
CYP17A1 // / / / // / / / // / / /
CYP2A13 -1.41 -1.34 1.66 2.54 3.41 -1.73 2.54 2.73 3.83 2.07 -2.15 1.15 3.09 1.81 2.98
CYP2C18 / / / / / / / / / / -2.16 -1.04 1.07 1.01 -1.31
CYP2D6 -1.31 -3.92* -1.36 -1.20 -1.03 / / / / / / / / / /
CYP2E1 -1.06 -2.20* -1.68 -1.21 1.06 / / / / / 1.01 -2.09 -1.54 -1.28 -1.02
CYP2F1 / / / / / 1.99 -1.23 2.21 -1.09 -1.57 -1.00 -1.63 1.56 -1.32 -2.95
CYP26A1 // / / / // / / / // / / /
CYP26B1 / / / / / 1.16 -1.01 1.06 2.37 -1.04 / / / / /
CYP3A4 1.19 -3.19* -2.22 -2.08 2.56* -1.54 16.93 1.80 1.92 1.40 -1.42 25.71* 2.69 1.62 1.78
CYP3A7 -2.11 -2.82 -2.21 -2.08 1.20 1.71 3.14 2.44 1.78 1.17 2.21 3.36* 2.13 1.49 1.58
CYP4B1 -1.01 -2.46 -1.06 -2.08 1.00 / / / / / / / / / /
CYP51A1 // / / / // / / / // / / /
CYP7A1 1.85 -2.28* -2.35 -8.09 -2.76 2.51 -1.23 -1.60 -1.79 -1.02 1.01 -2.40 -4.24 -1.25 -1.51
CYP7B1 2.25 -1.28 -1.72 -1.19 1.30 2.10 -1.00 -1.69 -1.17 1.30 / / / / /
CYP8B1 // / / / // / / / // / / /
Epoxide hydrolase 1 (s1) 3.06 1.55 1.20 -1.06 1.13 1.27 1.41 1.91 2.19 1.41 1.45 1.80 3.15 1.50 1.17
Epoxide hydrolase 1 (s2) / / / / / / / / / / 1.16 1.64 2.50 1.52 1.12
Epoxide hydrolase 2 // / / / // / / / // / / /
Flavin containing monooxygenase 1 1.30 -2.44* -1.46 -1.07 -1.13 / / / / / / / / / /
Flavin containing monooxygenase 2 // / / / // / / / // / / /
Flavin containing monooxygenase 4 // / / / // / / / // / / /
Flavin containing monooxygenase 5 -2.14* -3.17* -3.03 -1.60 -1.48 / / / / / / / / / /
Glutathione S-transferase A1 // / / / // / / / // / / /
Glutathione S-transferase theta 1-s1 // / / / // / / / // / / /
Glutathione S-transferase theta 1-s2 // / / / // / / / // / / /
Glutathione S-transferase theta 2 // / / / // / / / // / / /
Glutathione transferase M3 // / / / // / / / // / / /
Heme oxygenase (decycling) 1 16.63* 1.37 1.50 1.40 1.66 1.16 1.22 1.62 2.03 1.50 1.13 1.26 2.41 1.42 1.28
Heme oxygenase (decycling) 2 // / / / // / / / // / / /
Sulfotransferase family 1E1 -1.74 -2.58* -2.40 -1.88 -1.50 -1.04 -1.46 -1.98 -2.16 -1.93 -1.10 -1.70 -1.90 1.00 -2.37
Sulfotransferase family 1B1 / / / / / -2.28 -1.66 -1.97 -1.72 -1.71 / / / / /
Sulfotransferase family 2B1 // / / / // / / / // / / /
UDP glucuronosyltransferase 2B15 -2.21 -1.26 1.62 2.29 1.15 2.67 1.04 1.34 2.40 -1.06 / / / / /
UDP glycosyltransferase 8 // / / / // / / / // / / /
UDP-glucose ceramide 
Glucosyltransferase
// / / / // / / / // / / /
UDP-glucose ceramide 
Glucosyltransferase-like 1
-1.09 -1.08 -2.06 -1.49 -1.24 / / / / / / / / / /
ATP-binding cassette (ABCG2) // / / / // / / / // / / /
Solute carrier family 10 (SLC10A1) -1.20 -3.69* -2.03 -1.47 -1.38 // / / / // / / /
ATP-binding cassette (ABCB1) // / / / 1.02 2.32* 1.74 2.34 1.06 1.02 2.08* 1.57 1.33 1.27
Solute carrier family 22 (SLC22A1) 1.16 -2.49* -1.33 -1.20 -1.29 // / / / // / / /
Solute carrier family 22 (SLC22A7) // / / / // / / / // / / /
ATP-binding cassette (ABCC2) 2.94* 1.54* 1.07 -1.12 1.34 // / / / // / / /
Phenobarbital Rifampicin
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Beta-naphtoflavone
The numerical value indicates the fold changes for each cellular model after induction compared with the control condition;
differentially expressed genes that are upregulated by at least a factor of 2 or downregulated by at least a factor of −2 are colored in
red or green, respectively. A dash (/) is indicated in the table when there is no fold change in gene expression by at least a factor of 2 or
−2 in any of the cellular models. When at least one cellular model has a fold change higher than 2 or lower than −2, the gene expression
data are reported for all the models. A full rectangle is drawn when all cellular models are consistently regulated in the same direction
(five of five); a dashed rectangle is drawn when only four out of five cellular models are regulated in the same direction
Cell Biol Toxicol (2012) 28:69–87 79in the response whereas CYP2B6 and 3A4 showed more
variability in the response but always in the same direction.
Almost no induction could be observed in HepG2 cells,
except for CYP1A2 after BNF treatment.
Cytotoxicity experiment
Table 6 summarizes the LC50 values of the different
cellular models exposed to 16 hepatotoxic and 5
Table 5 Summary of CYP activity in the HH (3 donors), HepaRG, and HepG2 cells after exposure to vehicule, BNF, PB, and RIF
a)
Test System Vehicle BNF* PB
+ RIF°
pmol/min/mg protein
2.51 27.5 5.28 4.32
1.92 28.2 2.94 4.09
4.15 26.3 3.04 3.83
3.59 34.9 6.71 4.03
3.70 33.2 5.87 4.63
3.52 30.5 5.64 7.15
1.06 9.73 1.13 0.55
3.46 9.07 0.39 0.89
0.73 8.73 0.99 0.71
BLQ 15.9 2.24 0.43
0.49 18.8 2.18 2.04
BLQ 17.9 0.09 0.29
BLQ 2.30 - BLQ
0.13 1.90 - BLQ
0.26 1.10 - 0.10
pmol/min/mg protein
22.0 80.6 296 185
22.0 73.8 280 187
22.2 79.6 274 175
42.6 140 372 116
48.2 150 430 119
52.2 117 384 123
ND ND ND ND
ND ND ND ND
ND ND ND ND
4.50 8.84 38.0 12.3
4.17 6.95 37.6 11.7
BLQ 6.32 37.2 11.4
0.70 0.47 0.64 0.72
0.50 0.68 0.54 0.57
0.48 0.63 0.52 0.54
pmol/min/mg protein
513 138 1680 2032
573 138 1624 1976
503 130 1416 1904
722 463 1608 1584
808 456 1616 1656
808 517 1728 1632
102 34.6 530 856
67.2 35.4 516 928
82.4 35.9 488 880
24.9 4.48 984 1120
27.9 5.79 1072 1192
29.2 3.81 944 1168
3.63 6.17 5.63 4.32
5.51 4.33 4.82 4.62
5.11 5.32 4.65 5.80
* CYP1A2; 
+ CYP2B6; ° CYP3A4
Resorufin formation (CYP1A2)
HO-Bupropion formation (CYP2B6)
HO-Midazolam formation (CYP3A4)
HH1
HH2
HH3
HepaRG
HepG2
HH1
HH2
HH3
HepaRG
HepaRG
HepG2
HepG2
HH1
HH2
HH3
b)
Test System
HH1 9.55 (0.32) 1.31 (0.47) 1.43 (0.09)
HH2 9.12 (0.61) 1.69 (0.15) 1.46 (0.46)
HH3 10.3 (0.56) -1.06 (0.45) -1.25 (0.19)
HepaRG 35.7 (2.97) 3.06 (2.50) 1.87 (1.99)
HepG2 9.14 (3.09) - - -2.00 (1.99)
HH1 3.53 (0.17) 12.8 (0.51) 8.27 (0.29)
HH2 2.84 (0.35) 8.29 (0.64) 2.50 (0.08)
HH3 ND ND ND ND ND ND
HepaRG 1.70 (0.30) 8.66 (0.09) 2.72 (0.10)
HepG2 -1.08 (0.06) -1.20 (0.10) -1.15 (0.14)
HH1 -3.85 (0.01) 2.97 (0.26) 3.72 (0.12)
HH2 -1.64 (0.04) 2.12 (0.09) 2.08 (0.05)
HH3 -2.38 (0.01) 6.08 (0.25) 10.6 (0.46)
HepaRG -5.88 (0.04) 36.6 (2.40) 42.4 (1.34)
HepG2 1.11 (0.19) 1.06 (0.11) 1.03 (0.17)
* CYP1A1/2; 
+ CYP2B6; ° CYP3A4
CYP2B6
CYP3A4
BNF* PB
+ RIF°
CYP1A2
CYP1A2, 2B6, and 3A4 activities were measured using ethoxyresorufin O-deethylase, bupropion hydroxylation (BPH), and midazolam
as respective catalytic probes. Values in (a) represent the basal and induced activities; values in (b) represent the average fold change
(technical triplicates) compared to vehicle treated cells. Standard deviation is indicated between brackets. Fold changes >2 and <5 are
colored in yellow, >5 and <10 in orange, and >10 in red
ND no data reported for BPH activity due to technical problem, BLQ below detection limit
80 Cell Biol Toxicol (2012) 28:69–87nonhepatotoxic compounds using the xCELLigence
platform. Figure 2 shows the curves obtained with
the xCELLigence system in all cellular models ex-
posed to 10 or 100 μM aflatoxine B1. To better visu-
alize the data, no more than three cellular models are
presented on the same graph. LC50 values were calcu-
lated from these types of graphs by means of an excel
macro which was designed internally. A compound is
classified as highly cytotoxic when LC50 value is
below 10 μM, moderately cytotoxic when LC50 value
is between 10 and 50 μM, weakly cytotoxic when
LC50value isbetween50and100μM and not cytotoxic
when the LC50 value is above 100 μM. These cut-off
values were chosen arbitrary. All negative compounds
were correctly identified in all models. From the eight
severely hepatotoxic compounds, cerivastatin was
found highly cytotoxic in all cellular models. Danazol
had an LC50 value higher than 100 μM in all models,
whereas its Cmax (the maximum concentration of a
drug in the blood after dosing) was only 0.16 μMi ni n
vivo studies. Aflatoxin B1 was found highly cytotoxic
in HepaRG cells and HH and only moderately cytotoxic
in HepG2 cells. Amiodarone and astemizole were clas-
sified as highly cytotoxic in HH, moderately cytotoxic
in HepG2 and weakly cytotoxic in HepaRG cells. Flu-
tamide, ketoconazole and labetalol induced cytotoxicity
in HH only. For the eight moderately hepatotoxic com-
pounds,chlorpromazineandtamoxifenweremoderately
cytotoxic in HepG2 and HepaRG cells and highly cyto-
toxic in the 3 HH donors. Aspirin and clofibrate were
classified as non cytotoxic in all the models tested.
Cyclosporin A, furazolidone and imipramine were
foundmoderatelycytotoxicandtacrineweaklycytotoxic
in HH with LC50 values ranging between 24 and 81 μM.
Imipramine was determined weakly cytotoxic in HepG2
cells (average LC50 of 90 μM). Predictivity of the differ-
ent models (i.e., sensitivity and specificity) is presented
in Table 6. A sensitivity of 30–50% was found for HH
(depending on the donor). Lower sensitivities were ob-
served for HepaRG cells (12.5%) and HepG2 cells
Table 6 LC50 and predictivity data at 48 and 72 h exposure to 21 (non)hepatotoxic compounds for the different cellular models
Repeat
Timepoint 48h 72h 48h 72h 48h 72h 48h 72h 48h 72h 48h 72h 48h 72h 48h 72h 48h 72h
Aflatoxin B1 NA T / >100 >100 70.60 47.0 57.1 18.8 7.10 6.25 6.08 5.11 7.54 5.68 2.55 0.93 2.25 0.92 0.83 0.73
Amiodarone 0.81 BBW, H 8 22.3 19.8 36.7 37.9 37.1 34.9 57.0 55.0 57.1 61.0 >50 >50 10.5 4.16 4.91 3.38 7.14 <0.05
Astemizole 0.01 CA / 16.3 47.2 64.4 78.7 39.9 51.1 83.0 77.0 93.9 >100 55.8 55.2 2.75 2.49 6.25 5.85 3.80 2.32
Cerivastatin 0.03 Wd, I, H / 0.33 0.12 0.66 0.67 1.07 2.55 9.00 7.14 8.55 5.22 9.18 5.31 <0.1 <0.1 1.90 <0.1 8.60 <0.1
Danazol 0.16 W 8 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100
Flutamide 6 W, H,C,J,X,FH 8 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 99.3 91.5 67.5 6.29 >100 >100
Ketoconazole 7 BW,X,H,C 8 49.6 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 27.9 18.7 32.9 1.82 45.6 5.42
Labetalol 0.4 W,I,H,FH,X,C,HI 8 >100 >100 70.2 63.9 >100 >100 >100 >100 >100 >100 >100 >100 59.3 51.9 28.7 10.7 46.3 41.2
Aspirin 1650 I,H,Ht / >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100
Chlorpromazine 0.5 Ht, C 2 49.8 54.6 42.9 46.7 59.3 62.6 54.0 54.0 60.4 65.8 86.7 96.4 16.6 18.3 6.60 5.83 3.89 1.73
Clofibrate 470 I,Hm,C 3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100
Cyclosporin A 0.2 C,Ht 2 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 52.7 38.0 56.8 48.9 41.4 24.4
Furazolidone 4 C, HI / >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 36.6 27.5
Imipramine 0.6 H,LD,C 3 93.8 >100 83.3 90.9 >100 >100 >100 >100 >100 >100 >100 >100 65.3 63.5 61.6 58.4 47.9 45.3
Tacrine 0.1 W,H,B,Ht 7 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 81.2 76.8 67.2 58.7 59.7 54.4
Tamoxifen 0.4 W,I,H,B,C,HI 6 35.4 52.1 >100 >100 66.7 69.6 52.6 50.0 58.6 58.8 57.1 57.8 4.84 3.95 3.31 2.47 6.56 6.51
Betaine HCl 940 - no >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100
Flufenamic acid 46 - / >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100
Isoproterenol 0.006 - no >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100
Praziquantel 1.8 - / >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 89.2 >100 >100
Primidone 23 - no >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100
Cmax
(µM)*
Non 
hepatotoxic 
cpds
Toxicity* Compounds
DILI 
score
(LTKB)
23
Severely 
hepatotoxic
 cpds
Moderately
hepatotoxic
cpds
HepG2 HepaRG HH
1231231
6.3 6.3 6.3 12.5 12.5 12.5
100 100 100 100 80 100
Sensitivity (%)
Specificity (%)
31.3 50 43.8
100 100 100
LC50 data were determined by real-time cell analyzer (RTCA). HepG2, HepaRG cells, and cryopreserved human hepatocytes were
exposed to 21 compounds, with known hepatotoxicity. Each experiment has been repeated three times. The cells were incubated for
approximately 72 h with the compounds, and LC50 values were determined after 4, 24, 48, and 72 h. This table shows only the LC50
values calculated after 48 and 72 h. Color code: white LC50>50 μM, yellow 10 μM<LC50<50 μM, and red LC50<10 μM. Cmax are
indicated as well as mechanisms of toxicity
B hyperbilirubinemia, H hepatitis, BBW black box warning, BW boxed warning, CA cardiac arrhythmia, C cholestasis, FH: fulminating
hepatitis, HI hepatocellular injury with necrosis, Hm hepatomegaly, Ht Hepatotoxicity, I incidence of elevated liver function tests, J
jaundice, LD liver dysfunction, T chemical causing toxicity, W regulatory warning, Wd withdrawn, X deaths, NA not applicable, no no
dili concern, “/” cpd not present in the LTKB db (LTKB website: http://www.fda.gov/ScienceResearch/BioinformaticsTools/Liver-
ToxicityKnowledgeBase/default.htm)
*Information taken from O’Brien et al. (2006), except for chlorpromazine (Wen and Zhou 2009). Percentages sensitivity (detection of
positive compounds) and specificity (detection of negative compounds) are presented for each repeat that has been done in each cellular
model. Dili scores, as reported in the LTKB database are indicated in the table
Cell Biol Toxicol (2012) 28:69–87 81(6.3%) (Table 6). A specificity of 100% was obtained in
all cellular models.
Discussion
Drug-induced hepatotoxicity is one of the major rea-
sons cited for drug withdrawal (O’Brien et al. 2006;
McDonald and Robertson 2009). Therefore, it is of
extreme importance to detect human hepatotoxic can-
didates as early as possible during the drug develop-
ment process and before clinical phases. Simple
cytotoxicity assays using HepG2 cells are relatively
insensitive to detect human hepatotoxic drugs (Xu et
al. 2004). Nevertheless, this is in contrast to the work
of O’Brien et al. (2006) who calculated a sensitivity of
0 20 40 60 80
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
2.25
2.50 HH1
HH2
HH3
DMSO-HH2
time (h)
C
e
l
l
 
i
n
d
e
x
0 20 40 60 80
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
2.25
2.50
HepaRG
HepG2
DMSO-HepG2
DMSO-HepaRG
time (h)
C
e
l
l
 
i
n
d
e
x
0 20 40 60 80
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
2.25
2.50
HH1
HH2
HH3
DMSO-HH2
time (h)
C
e
l
l
 
i
n
d
e
x
0 20 40 60 80
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
2.25
2.50
HepaRG
HepG2
DMSO-HepG2
DMSO-HepaRG
time (h)
C
e
l
l
 
i
n
d
e
x
a
c
b
d
Fig. 2 Cytotoxicity curves of HepG2, HepaRG and human
hepatocytes exposed to solvent and two concentrations of afla-
toxine B1. To better visualize the data, no more than three
cellular models are presented on the same graph. Cryopreserved
human hepatocytes, HepaRG, and HepG2 cells were incubated
with 10 μM( a, b) and 100 μM( c, d) aflatoxine B1 for
approximately 72 h. Cell index curves were generated in real
time using the xCELLigence instrument. Each data point was
normalized against the time just before compound addition and
was calculated from triplicate values. Curves represent averages.
For more details of the experiment, please refer to “Materials
and method”
82 Cell Biol Toxicol (2012) 28:69–8790% for the detection of hepatotoxic drugs in HepG2
cells usinga cellimagingapproach (LC50<30μMb a s e d
on a set of 243 compounds). This is very surprising,
knowingthat HepG2 cells have low metabolic capacities
according to the literature and the present data. This
discrepancy in sensitivity could be due to (1) the differ-
ent endpoints measured compared with ours, (2) the
different cut-off values used to classify a compound as
toxic (30 vs. 10 μM), and (3) the different sources of
HepG2 cells which could contain different basal activi-
ties of phases I and II drug-metabolizing enzymes
(Hewitt and Hewitt 2004). In the present study, the
HepG2 sensitivity was only 6.3% with a set of 16human
hepatotoxic drugs. We consider arbitrarily that a drug is
classified as hepatotoxic when LC50<10 μM. In many
cases, depending on the stringency required, LC50<10–
50 μM are generally used to classify pharmaceutical
compounds (Evans et al. 2001; Dambach et al. 2005;
O’Brien et al. 2006).
The present publication compares HepG2, HepaRG
cells, and primary human hepatocytes with regard to
their metabolism and potential to detect hepatotoxicity.
To the best of our knowledge, this combined approach
hasbeenveryrarelyattemptedinthesamestudy.Clearly,
these cellular models have already been characterized
separately at the metabolism levels (e.g., Guillouzo et
al. 2007; Westerink and Schoonen 2007; Lambert et al.
2009), and there are also some other publications related
to the predictivity of HepG2 (O’Brien et al. 2006)a n d
primary HH (Xu et al. 2008) to detect hepatotoxicity.
Finally, the results generated on HepaRG cells for the
detection of hepatotoxic compounds in the present study
are novel with the exception of aflatoxin B1 and ketoco-
nazole (Pernelle et al. 2011).
In the present study, the three cellular models were
characterized with respect to their gene expression
profiles and CYP activities (CYP1A2, 2B6, and
3A4) in control cells and after exposure to BNF, PB,
and RIF. The PCA demonstrated high reproducibility
of the replicates and a separation of the three cellular
models in both vehicle controls and in cells exposed to
the inducers. The largest difference in the number of
differentially expressed probes (2-fold change) was
found between HH and HepG2 cells after exposure
to solvent and to the different inducers. Almost every
phase I, II and III genes, present on the micro-array,
was less expressed in control HepG2 cells compared
with control HepaRG cells and HH. These low CYP
mRNA levels in HepG2 cells were also reported in
other studies (Westerink and Schoonen 2007). Jennen
et al. (2010) demonstrated that at the basal gene ex-
pression level, HepaRG cells are closer to primary HH
compared with HepG2 cells. In the present study,
according to PCA, this was only the case for one of
the three donors. However, after exposure to inducers,
HepaRG cells were more closely related in space to
the HH donors than HepG2 cells. Only limited
changes in gene expression pattern, after exposure to
any of the three inducers could be observed in HepG2
cells compared with the other models. At the mRNA
level, BNF turned out to be the best inducer in HepG2,
HepaRG, and HH2 cells with the highest number of
differentially expressed probes. Among the three HH
donors, differences were observed in their responsive-
ness to the inducers. This variability can most likely be
ascribed to inter-individual differences in basal ex-
pression, but also in sensitivity to the inducers (Olinga
et al. 2008). Gene expression of phase I enzymes
showed that BNF clearly induced the CYP1A2 gene
in all three models and down-regulated the CYP3A4
gene in HepaRG cells and HH. The poor inducibility
of HepG2 cells, except for the CYP1A1 enzyme, has
been reported before (Donato et al. 2004). This could
be related to the fact that the aryl hydrocarbon receptor
(AhR) is expressed in most immortalized cell lines and
consequently the CYP1A gene which is regulated by
AhR is inducible in those cells (Donato et al. 2008). At
the gene expression level, BNF induced CYP1A2
gene ca. four times in all three cellular models (except
in one donor). The other inducers, PB and RIF showed
specific induction of respectively CYP2B6 and
CYP3A4 genes in HH and HepaRG cells but not in
HepG2 cells. These findings are in agreement with the
literature (Xu et al. 2005; Faucette et al. 2004; Jackson
2004). In HH, Faucette et al. (2004) showed that
CYP2B6 is highly inducible by known CYP3A4
inducers. Rhodes et al. (2011) also mentioned the
same level of induction with PB and RIF in HH as in
our experiments. Our data also show an induction of
CYP1A2 in HepaRG following BNF treatment as in
Lübberstedt et al. (2010). However, in contrast to the
later experiment, a marked induction of CYP3A4 after
RIF exposure was observed in HepaRG cells. The cor-
relation between gene expression and activity for
CYP1A2 was optimal for two human donors but was
weak for HepG2, HepaRG, and the third human donor.
On the other hand, the correlation between the gene
expression and CYP3A4 activity was satisfactory in all
Cell Biol Toxicol (2012) 28:69–87 83models, except for HepG2. It is well known that the
mRNA leveldoesnot necessarilycorrelate wellwiththe
enzyme activities due to posttranscriptional regulations
such as acetylation, disulfide bond formation, glycosyl-
ation, and phosphorylation (Glanemann et al. 2003). In
summary, the gene expression data show that HepG2
cells are poorly inducible whereas HepaRG cells are
inducible and are closer to HH after exposure to BNF,
PB and RIF. These later increased specifically CYP
activity in HH and HepaRG cells but rarely in HepG2
cells, except for BNF. For instance, in HepaRG cells
CYP activity was increased 35.7 (BNF), 8.7 (PB), and
42.4 (RIF) times compared with 9.7 (BNF), 10.6 (PB),
and 5.5 (RIF) times in HH for CYP1A2, 2B6, and 3A4,
respectively. Consequently, HepaRG cells seem to be a
very interesting model to use in metabolism studies as a
substituteand/orincomplementtoprimary hepatocytes.
Recently, Turpeinen et al. (2009), Anthérieu et al.
(2010) and Lübberstedt et al. (2010) also concluded that
HepaRG cells are a very promising cell line for various
applicationsinxenobioticmetabolism.Themain advan-
tages of HepaRG cells are linked to the higher response
with the different inducers and compared with primary
HH they showed much reduced variability.
Subsequently, the three models were exposed to
16 known hepatotoxic and five nonhepatotoxic com-
pounds and cytotoxicity was determined using the
xCELLigence platform (real-time cell analyzer (RTCA)).
RTCA was used to measure cytotoxicity. The main
advantages of the xCELLigence platform are: no cellular
labeling, noninvasive measurements, kinetic evaluation
in a real-time mode, reasonable throughput, with poten-
tial applications in toxicology and pharmacology
(Atienzar et al. 2011). Nevertheless, to convince more
researchers to use RTCA in early toxicity screening, it
will be necessary to show that there is a good correlation
between cellular impedance measurements and classical
toxicity endpoints with a large number of compounds
(Atienzar et al. 2011). Different studies (but limited in
numbers) have revealed a high correlation between
impedance-based determination of viable adherent cells
andMTTevaluation in different cell types (Atienzar et al.
2011). In addition, our data show a good correlation
between CI (RTCA) and cell number (cell imaging)
when HepG2 and HepaRG cells were exposed to the
same set of 21 compounds with coefficient of correlation
of 76% and 88%, respectively (data not shown). In
another study the coefficient of correlation between
ATP and CI (RTCA) was 88.5% in HepG2 cells exposed
to 50 compounds (data not presented). Based on these
preliminary data, CI measured by RTCA seems to corre-
late well with classical toxicity endpoints. Since the use
of freshly isolated primary hepatocytes in drug screening
is rather difficult (due to its limited availability and high
cost) cryopreserved hepatocytes were used instead.
CYP1A and 3A studies performed by Roymans et al.
(2004) showed similar results between freshly isolated
and cryopreserved HH. In the present study, all cellular
models correctly classified all nonhepatotoxic com-
pounds (n05). Despite the inducible properties of
HepaRG cells, the detection of the hepatotoxic com-
pounds in these cells was not remarkably better than in
HepG2 cells with a sensitivity of 12.5% which is much
lower compared with HH (42% on average). A given
compound is classified arbitrarily as cytotoxic when
LC50 value <10 μM. The present study is not in agree-
ment with the high sensitivity (90%) reported in HepG2
cells by O’Brien et al. (2006) although LC50 values <
30 μM were used as a cutoff. However, HepG2 cells
were capable of detecting cytotoxicity effects of
aflatoxine B1, despite their low metabolic profile.
In comparison to HepaRG cells, higher concentra-
tions and longer incubations were needed to reach
the LC50 values. Our study reveals that a high
metabolic capacity in cell lines does not necessar-
ily guarantee to detect more hepatotoxic drugs.
There are several possibilities that could explain
why HepaRG cells were not as predictive as expected
for the detection of human hepatotoxins. Firstly, to
differentiate the HepaRG cells, our supplier Biopredic
recommended using 2% DMSO. Such a concentration
may be optimal for induction studies but not for cyto-
toxicity experiments. In HH, a concentration dependent
increase in CYP3A4 activity was observed at concen-
trations between 0.1% and 1% DMSO, followed by a
plateaueffectintherange1–2%DMSO(LeCluyseetal.
2000). Our data suggest that in HepaRG cells, 2%
DMSO is adequate for CYP induction. Nevertheless,
Gilot et al. (2002) have described DMSO as an inhibitor
of apoptosis in hepatocytes. This protective effect of
DMSO was related to its free radical scavenging prop-
ertyand through a dualblockageofcleaved caspase and
ASK1/JNK activities. Consequently, using lower per-
centagesofDMSOcouldimprove thedetectionofsome
hepatotoxins. Secondly, higher levels of basal CYP
activities may be required in HepaRG cells to optimally
metabolize drugs. The third explanation could be linked
to the high phases II and III activities that could
84 Cell Biol Toxicol (2012) 28:69–87efficiently detoxifythe metabolites preventing thus their
toxic action (Kanebratt and Andersson 2008).
Nuclear receptors (i.e., CAR, PXR, and AhR)
expression play key role in metabolism. The expres-
sion level of CAR and PXR is low in HepG2 cells
(Naspinski et al. 2008; Kanno and Inouye 2010) and
high in HepaRG cells and HH (Aninat et al. 2006).
Nevertheless, the presence or absence of nuclear
receptors does not totally explain why some cellular
models are less predictive than others for the detection
of hepatotoxicity as other factors such as phase II
enzymes and transporters could also play key roles.
Due to low sensitivity of the different models to detect
hepatotoxic compounds, one could wonder whether
measuring cytotoxicity endpoints is of any relevance
to predict hepatotoxicity. Indeed, because of its crude-
ness, cell death may not be the most appropriate end-
point to detect all mechanisms of hepatotoxicity in
typical cellular models (primary hepatocytes, HepG2,
etc.). This is particularly true when a given mechanism
of hepatotoxicity does not necessarily lead to cell
death although impairing internal cellular processes.
For instance, the relationship between toxicity to hep-
atocytes in vitro and drug induced liver injury in vivo
(in pre-clinical species or in man) remains poorly
defined (Greer et al. 2010). Better prediction of hepa-
totoxicitycould beobtainedbyevaluatingmorespecific
endpoints (than cell death) such as mitochondrial im-
pairment, biliary transport, CYP450 inhibition and
metabolite-mediated toxicity (Greer et al. 2010). Never-
theless,Andrewsetal.(2003)developeda highthrough-
put assay, measuring cell death on CYP450-transfected,
immortalized human hepatocyte cell lines (THLE) with
defined CYP450 activity (CYP3A4, 2C9, 2C19, and
2D6). The assay correctly predicted 585/587 nonhepa-
totoxic drugs,15/21 severelyhepatotoxic drugs,and 51/
71 variably hepatotoxic drugs (Dambach et al. 2005). In
the validation set, ca. 72% of drugs with known liver
toxicity had IC50’sl e s st h a n5 0μM in one or more cell
lines (Andrews et al. 2003).
In summary, HepG2 cells responded very weakly to
the different inducers compared with the other cell
models at the gene expression and CYP activity levels.
However, although HepaRG cells seem to be a suit-
able model for the induction studies, cells are not as
predictive as primary HH and were quite comparable
to the HepG2 cells for the prediction of human hepa-
totoxic drugs. Consequently, more studies are needed
to determine which of the models would be more
suited to detect hepatotoxic compounds with the hope
to get sensitivity and specificity of at least 80–90%.
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